Prostate Cancer Screening Guidelines in 2017

Size: px
Start display at page:

Download "Prostate Cancer Screening Guidelines in 2017"

Transcription

1 Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital

2 Prostate Specific Antigen (PSA)

3 Prostate Specific Antigen (PSA) Androgen-regulated protease enzyme Function : liquefy semen Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer 2002;2(12):

4 Prostate Specific Antigen (PSA) Normally found in low concentration in serum (ng/ml) Within serum, PSA circulates in bound (complexed PSA) and unbound (free PSA [fpsa]) forms Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:

5 Prostate Specific Antigen (PSA) PSA produced from malignant cells serum complexed PSA escape proteolytic processing free PSA Woodrum DL, Brawer MK, Partin AW, et al. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5 12.

6 Prostate Specific Antigen (PSA) Highly organ specific Primarily produced by prostatic luminal cells Not cancer specific Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:

7 Elevated serum PSA Disruption of cellular architecture within the prostate gland Barrier loss (prostate disease): BPH, prostatitis, prostate cancer Prostate manipulation: prostate massage, long distance bicycle riding Urinary retention Prostatic trauma: prostate biopsy Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317: Mejak SL, Bayliss J, Hanks SD. Long distance bicycle riding causes prostatespecific antigen to increase in men aged 50 years and over. PLoS One 2013;8:e56030.

8 Prostate Specific Antigen (PSA) The 5α-reductase inhibitors (5ARI), such as finasteride and dutasteride, lower PSA levels 50% after 12 months of treatment Doubling rule May overestimate PSA values in the first 6 months of treatment and underestimate PSA levels after several years of treatment Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1993;22: Marks LS, Andriole GL, Fitzpatrick JM, et al. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol 2006;176:

9 Early Detection and Screening

10 Early Detection and Screening Detection of disease at an early, pre-symptomatic stage when a man would have no reason to seek medical care An intervention referred to as secondary prevention In the US, early detection by PSA-based screening followed by prostate biopsy for diagnostic confirmation Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:

11 Benefits of PSA Screening

12 Benefits of PSA Screening Lower stage and grade of cancer at diagnosis Reduction in prostate cancer specific mortality rates Aus G, Bergdahl S, Lodding P et al: Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer results from a prospective, population based randomized controlled trial. Eur Urol 2007; 51: 659. Schröder FH, Hugosson J, Carlsson S et al: Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2012; 62: 745. Labrie F, Canda sb, Cusan L et al: Screening decreases prostate cancer mortality: 11-year follow up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004; 59: 311.

13 Why the recommendation against screening for prostate cancer?

14 Why the recommendation against screening for prostate cancer? Screening and consequent treatment, as currently practiced, are often harmful: Too much screening of elderly men with a short life expectancy Too liberal criteria for biopsy Too aggressive treatment of low risk cancers Inadequate treatment of high risk cancers Treatment largely administered by low volume providers (higher risks of side effects and lower risks of cure) Vickers AJ, Lilja H. Time for another rethink on prostate cancer screening. Nat Rev Clin Oncol. 2011; 9:7-8.

15

16 Overdiagnosis The detection of a prostate cancer that would have remained undetected during life in the absence of screening

17 Overdiagnosis Of all screen-detected cancers, an estimated 10-56% would not have become apparent or caused symptoms in the patients lifetimes. Draisma G, Etzioni R,Tsodikov et al. Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context. J Natl Cancer Inst 2009;101: Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012;367:

18 Harms: Prostate biopsy Study population 5% random sample of Medicare participants, (n = 17,472) 30-day hospitalization rate (%) Infection Bleeding Not reported Urinary obstruction Not reported 30-day mortality rate (%) 0.31 All men receiving an initial prostate biopsy not resulting in diagnosis of cancer in Ontario, Canada, (n=41,682) Consecutive patients at a single academic medical center, (n = 1,000) Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011;186: Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, Loblaw DA, Trachtenberg J, Stanimirovic A, Simor AE, Seth A, Urbach DR, Narod SA. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010;183: Pinkhasov GI, Lin YK, Palmerola R, Smith P, Mahon F, Kaag MG, Dagen JE, Harpster LE, Reese CT, Raman JD. Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases. BJU Int 2012;110:

19 Harms Psychological impact of prostate cancer screening Distress involved in the decision making process, the biopsy and deciding among treatment options Severe psychological stress with one study showing an increased rate of suicide and cardiovascular events in newly diagnosed men Fang F et al: Immediate Risk of Suicide and Cardiovascular Death After a Prostate Cancer Diagnosis: Cohort Study in the United States. JNCI 2010; 102: 307.

20 PSA Screening and Overdiagnosis Claire L. Tonry et al. The role of proteomics in biomarker development for improved patient diagnosis and clinical decision making in prostate cancer. Diagnostics 2016, 6, 27. Roobol, M.J.; Carlsson, S.V. Risk stratification in prostate cancer screening. Nat. Rev. Urol. 2013, 10,

21 Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostatespecific antigen screening. N Engl J Med 2012;367:

22 PSA Screening Guidelines

23 PSA Screening Guidelines AUA EAU NCCN

24 PSA Screening Guidelines AUA EAU NCCN

25

26

27

28

29

30

31

32 Early Detection Guidelines: AUA 2013 For men ages 55 to 69 years Weighing the benefits of preventing prostate cancer mortality in 1 man for every 1,000 men screened over a decade against the known potential harms associated with screening and treatment Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:

33 Early Detection Guidelines: AUA Recommends against PSA screening in men under age 40 years 2. Does not recommend routine screening for men years at average risk (Family History, African-American) 3. Strongly recommends shared decision making for men years 4. Screening interval should be 2 years 5. Does not recommend routine screening for men 70 years or those with year life expectancy Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:

34 PSA Screening Guidelines AUA EAU NCCN

35

36

37

38

39

40 PSA Screening Guidelines AUA EAU NCCN

41 NCCN Guidelines years

42 Percent free PSA<10%, PHI>35 or 4K score Multiparametric MRI

43 Conclusion How to Increase the Benefits and Reduce the Risks of Screening for Prostate Cancer Risk-adjust screening by age and PSA (reduce false positives) Reduce false positive PSA results by repeating (verifying) positives and by adding additional markers (4Kpanel or -2(pro)PSA) (reduce indications for biopsy) Active surveillance for low-risk cancers (reduce harms of unnecessary therapy) Refer patients who need treatment to high-volume physicians or centers (reduce harm of necessary therapy) Vickers A, Roobol M, Lilja H. Annu. Rev. Med :

44 Thank You

Elevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017

Elevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,

More information

Controversies in Prostate Cancer Screening

Controversies in Prostate Cancer Screening Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations

More information

Prostate-Specific Antigen (PSA) Test

Prostate-Specific Antigen (PSA) Test Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the

More information

Questions and Answers about Prostate Cancer Screening with the Prostate-Specific Antigen Test

Questions and Answers about Prostate Cancer Screening with the Prostate-Specific Antigen Test Questions and Answers about Prostate Cancer Screening with the Prostate-Specific Antigen Test About Cancer Care Ontario s recommendations for prostate-specific antigen (PSA) screening 1. What does Cancer

More information

Prostate Cancer Screening: Con. Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto

Prostate Cancer Screening: Con. Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto Prostate Cancer Screening: Con Laurence Klotz Professor of Surgery, Sunnybrook HSC University of Toronto / Why not PSA screening? Overdiagnosis Overtreatment Risk benefit ratio unfavorable Flaws of PSA

More information

Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality

Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester

More information

Clinical Policy Title: Prostate-specific antigen screening

Clinical Policy Title: Prostate-specific antigen screening Clinical Policy Title: Prostate-specific antigen screening Clinical Policy Number: 13.01.06 Effective Date: May 1, 2017 Initial Review Date: April 19, 2017 Most Recent Review Date: April 19, 2017 Next

More information

PSA Screening and Prostate Cancer. Rishi Modh, MD

PSA Screening and Prostate Cancer. Rishi Modh, MD PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University

More information

PROSTATE CANCER SCREENING: AN UPDATE

PROSTATE CANCER SCREENING: AN UPDATE PROSTATE CANCER SCREENING: AN UPDATE William G. Nelson, M.D., Ph.D. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins American Association for Cancer Research William G. Nelson, M.D., Ph.D. Disclosures

More information

Urological Society of Australia and New Zealand PSA Testing Policy 2009

Urological Society of Australia and New Zealand PSA Testing Policy 2009 Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia

More information

10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION

10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa

More information

PSA and the Future. Axel Heidenreich, Department of Urology

PSA and the Future. Axel Heidenreich, Department of Urology PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3

More information

Table 1. Descriptive characteristics, total prostate-specific antigen, and percentage of free/total prostate-specific antigen distribution Age Groups

Table 1. Descriptive characteristics, total prostate-specific antigen, and percentage of free/total prostate-specific antigen distribution Age Groups Oncology Population-based Analysis of Normal Total PSA and Percentage of Free/Total PSA Values: Results From Screening Cohort Umberto Capitanio, Paul Perrotte, Laurent Zini, Nazareno Suardi, Elie Antebi,

More information

Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015

Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials

More information

PSA screening. To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine

PSA screening. To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine PSA screening To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine Conflict of Interest Declaration: Nothing to Disclose

More information

TITLE: The Influence of Patient Heterogeneity on the Harms and Benefits of Prostate Cancer Screening

TITLE: The Influence of Patient Heterogeneity on the Harms and Benefits of Prostate Cancer Screening TITLE: The Influence of Patient Heterogeneity on the Harms and Benefits of Prostate Cancer Screening RUNNING HEAD: Patient Heterogeneity in Prostate Cancer Screening June 17, 2016 Daniel J. Underwood,

More information

Examining the Efficacy of Screening with Prostate- Specific Antigen Testing in Reducing Prostate Cancer Mortality

Examining the Efficacy of Screening with Prostate- Specific Antigen Testing in Reducing Prostate Cancer Mortality St. Catherine University SOPHIA Master of Arts/Science in Nursing Scholarly Projects Nursing 5-2012 Examining the Efficacy of Screening with Prostate- Specific Antigen Testing in Reducing Prostate Cancer

More information

#1 cancer. #2 killer. Boulder has higher rate of prostate cancer compared to other areas surrounding Rocky Flats

#1 cancer. #2 killer. Boulder has higher rate of prostate cancer compared to other areas surrounding Rocky Flats Prostate cancer is a VERY COMMON DISEASE BREAKTHROUGHS IN THE DETECTION OF PROSTATE CANCER Carolyn M. Fronczak M.D., M.S.P.H. Urologic Surgery 303-647-9129 #1 cancer #2 killer Ca Cancer J Clin 2018;68:7

More information

Original Article - Urological Oncology. Ho Gyun Park 1, Oh Seok Ko 1, Young Gon Kim 1, Jong Kwan Park 1-4

Original Article - Urological Oncology. Ho Gyun Park 1, Oh Seok Ko 1, Young Gon Kim 1, Jong Kwan Park 1-4 www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.4.249 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.4.249&domain=pdf&date_stamp=2014-04-17

More information

PSA Screening for Prostate Cancer at Western Medical Clinic Kardy Fedorowich University of Manitoba Max Rady College of Medicine

PSA Screening for Prostate Cancer at Western Medical Clinic Kardy Fedorowich University of Manitoba Max Rady College of Medicine PSA Screening for Prostate Cancer at Western Medical Clinic Kardy Fedorowich University of Manitoba Max Rady College of Medicine Abstract While PSA screening for prostate cancer remains a widely used tool

More information

Cigna Medical Coverage Policy

Cigna Medical Coverage Policy Cigna Medical Coverage Policy Subject Prostate-Specific Antigen (PSA) Screening for Prostate Cancer Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 12 References...

More information

Enzyme Immunoassay for the Quantitative Determination of Free Prostate Specific Antigen (f-psa) in Human Serum

Enzyme Immunoassay for the Quantitative Determination of Free Prostate Specific Antigen (f-psa) in Human Serum Enzyme Immunoassay for the Quantitative Determination of Free Prostate Specific Antigen (f-psa) in Human Serum FOR RESEARCH USE ONLY Store at 2 to 8 C. PROPRIETARY AND COMMON NAMES f-psa Enzyme Immunoassay

More information

Should A PSA threshold of 1.5 ng/ml be the threshold for further diagnostic tests?

Should A PSA threshold of 1.5 ng/ml be the threshold for further diagnostic tests? Should A PSA threshold of 1.5 ng/ml be the threshold for further diagnostic tests? Hanan Goldberg, MD Princess Margaret Cancer Centre, UHN, Sunnybrook Health science Centre, University of Toronto, Toronto,

More information

The role of PSA in detection and management of prostate cancer

The role of PSA in detection and management of prostate cancer The role of PSA in detection and management of prostate cancer Kirby R. The role of PSA in detection and management of prostate cancer. Practitioner 2016; 260(1792):17-21 Professor Roger Kirby MA MD FRCS

More information

Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer

Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Prostate Cancer in Ireland & Worldwide In Ireland, prostate cancer

More information

PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC

PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC Disclosures Faculty / Speaker s name: Darrel Drachenberg Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria:

More information

Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer

Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer Urological Oncology CHUN et al. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer Felix K.-H. Chun, Georg C.

More information

Elsevier Editorial System(tm) for European Urology Manuscript Draft

Elsevier Editorial System(tm) for European Urology Manuscript Draft Elsevier Editorial System(tm) for European Urology Manuscript Draft Manuscript Number: EURUROL-D-13-00306 Title: Post-Prostatectomy Incontinence and Pelvic Floor Muscle Training: A Defining Problem Article

More information

The Evolving Role of PSA for Prostate Cancer. The Evolving Role of PSA for Prostate Cancer: 10/30/2017

The Evolving Role of PSA for Prostate Cancer. The Evolving Role of PSA for Prostate Cancer: 10/30/2017 The Evolving Role of PSA for Prostate Cancer Adele Marie Caruso, DNP, CRNP Adult Nurse Practitioner Perelman School of Medicine at the University of Pennsylvania November 4, 2017 The Evolving Role of PSA

More information

Pre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest

Pre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest Pre-test Matthew R. Cooperberg, MD, MPH UCSF 40 th Annual Advances in Internal Medicine Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest 1. I do not offer routine PSA screening, and

More information

Title: Prostate Specific Antigen (PSA) for Prostate Cancer Screening: A Clinical Review

Title: Prostate Specific Antigen (PSA) for Prostate Cancer Screening: A Clinical Review Title: Prostate Specific Antigen (PSA) for Prostate Cancer Screening: A Clinical Review Date: November 26, 2007 Context and policy issues: Prostate cancer is the most common tumor in men, and is one of

More information

Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients

Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients (2003) 6, 256 260 & 2003 Nature Publishing Group All rights reserved 1365-7852/03 $25.00 www.nature.com/pcan Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients 1, *

More information

J Clin Oncol 30: by American Society of Clinical Oncology

J Clin Oncol 30: by American Society of Clinical Oncology VOLUME 30 NUMBER 24 AUGUST 20 2012 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A L A R T I C L E Screening for Prostate Cancer With Prostate-Specific Antigen Testing: American Society of Clinical Oncology

More information

Prostatic Diseases and Male Voiding Dysfunction

Prostatic Diseases and Male Voiding Dysfunction Prostatic Diseases and Male Voiding Dysfunction Prostatic-specific Antigen Velocity After Holmium Laser Enucleation of the Prostate: Possible Predictor for the Assessment of Treatment Effect Durability

More information

Prostate Cancer Screening. Eric Shreve, MD Bend Urology Associates

Prostate Cancer Screening. Eric Shreve, MD Bend Urology Associates Prostate Cancer Screening Eric Shreve, MD Bend Urology Associates University of Cincinnati Medical Center University of Iowa Hospitals and Clinics PSA Human kallikrein 3 Semenogelin is substrate Concentration

More information

Increasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP

Increasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of

More information

What to Do with an Abnormal PSA Test. Feinberg School of Medicine, Chicago, Illinois, USA

What to Do with an Abnormal PSA Test. Feinberg School of Medicine, Chicago, Illinois, USA The Oncologist Genitourinary Cancer What to Do with an Abnormal PSA Test STACY LOEB, a WILLIAM J. CATALONA b a Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA; b The Northwestern

More information

Prostate-Specific Antigen Screening in Prostate Cancer: Perspectives on the Evidence

Prostate-Specific Antigen Screening in Prostate Cancer: Perspectives on the Evidence DOI:10.1093/jnci/dju010 First published online March 4, 2014 The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. Commentary

More information

PSA as a Screening Test - AGP' GP's Perspective

PSA as a Screening Test - AGP' GP's Perspective PSA as a Screening Test - AGP' GP's Perspective Chris Del Mar cdelmar@bond.edu.auedu au Member of the RACGP Red Book Committee Background: prostate cancer is serious 9 th ranked cause of disease burden

More information

Fellow GU Lecture Series, Prostate Cancer. Asit Paul, MD, PhD 02/20/2018

Fellow GU Lecture Series, Prostate Cancer. Asit Paul, MD, PhD 02/20/2018 Fellow GU Lecture Series, 2018 Prostate Cancer Asit Paul, MD, PhD 02/20/2018 Disease Burden Screening Risk assessment Treatment Global Burden of Prostate Cancer Prostate cancer ranked 13 th among cancer

More information

Ambulatory and Office Urology Optimal Measure of PSA Kinetics to Identify Prostate Cancer

Ambulatory and Office Urology Optimal Measure of PSA Kinetics to Identify Prostate Cancer Ambulatory and Office Urology Optimal Measure of PSA Kinetics to Identify Prostate Cancer Luigi Benecchi, Anna Maria Pieri, Carmelo Destro Pastizzaro, and Michele Potenzoni OBJECTIVES METHODS RESULTS CONCLUSIONS

More information

EUROPEAN UROLOGY 62 (2012)

EUROPEAN UROLOGY 62 (2012) EUROPEAN UROLOGY 62 (2012) 745 752 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Allison S. Glass, Matthew R. Cooperberg and

More information

Although the test that measures total prostate-specific antigen (PSA) has been

Although the test that measures total prostate-specific antigen (PSA) has been ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the

More information

Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases

Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases Original Article Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases Edmund Chiong, 1,2 Alvin Fung Wean Wong, 2 Yiong Huak Chan 3 and Chong Min Chin, 1,2 1 Department of Surgery,

More information

Prostate Cancer Screening:

Prostate Cancer Screening: Prostate Cancer Screening: The Other Side of the Story Tracie Gadler RN, MSN, RNFA, NP-C (Edited by Carol Salem MD) Urologic Oncology Surgery Robotic Surgical Services Nurse Practitioner, Scripps Mercy

More information

Prostate Cancer: from Beginning to End

Prostate Cancer: from Beginning to End Prostate Cancer: from Beginning to End Matthew D. Katz, M.D. Assistant Professor Urologic Oncology Robotic and Laparoscopic Surgery University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer

More information

PROSTATE CANCER SURVEILLANCE

PROSTATE CANCER SURVEILLANCE PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare

More information

Prostate-Specific Antigen in 2006: Effective Use in Benign Prostatic Hyperplasia and Prostate Cancer

Prostate-Specific Antigen in 2006: Effective Use in Benign Prostatic Hyperplasia and Prostate Cancer Volume 1, Number 3 ISSN: 1932-9245 Weill Medical College of Cornell University Reports on Men s Urologic Health 1 Editor: Steven A. Kaplan, MD, Professor of Urology, and Chief, Institute for Bladder and

More information

Prostate cancer screening: Attitudes and practices of family physicians in Ontario

Prostate cancer screening: Attitudes and practices of family physicians in Ontario Original research Prostate cancer screening: Attitudes and practices of family physicians in Ontario Christopher B. Allard, MD; * Shawn Dason; * Janis Lusis, MD; Anil Kapoor, MD, FRCSC * *McMaster Institute

More information

Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less than 10 ng/ml

Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less than 10 ng/ml ORIGINAL ARTICLE Oncology & Hematology http://dx.doi.org/10.3346/jkms.2014.29.3.338 J Korean Med Sci 2014; 29: 338-342 Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less

More information

ORIGINAL ARTICLE. Omer Gokhan Doluoglu 1, Cavit Ceylan 2, Fatih Kilinc 1, Eymen Gazel 2, Berkan Resorlu 1, Oner Odabas 2

ORIGINAL ARTICLE. Omer Gokhan Doluoglu 1, Cavit Ceylan 2, Fatih Kilinc 1, Eymen Gazel 2, Berkan Resorlu 1, Oner Odabas 2 ORIGINAL ARTICLE Vol. 42 (2): 346-350, March - April, 2016 doi: 10.1590/S1677-5538.IBJU.2015.0082 Is there any association between National Institute of Health category IV prostatitis and prostate-specific

More information

To be covered. Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for?

To be covered. Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for? To be covered Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for? Europa Uomo meeting Stockholm 29 Chris H.Bangma Rotterdam, The Netherlands

More information

Prostate Cancer Incidence

Prostate Cancer Incidence Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases

More information

Mr Declan Cahill Consultant Urological Surgeon The Royal Marsden

Mr Declan Cahill Consultant Urological Surgeon The Royal Marsden Diagnosing prostate cancer Mr Declan Cahill Consultant Urological Surgeon 2 Marsden GP Education Day 22 February 2016 Should I have a PSA test? Can I have a PSA test? prostatecanceruk.org 4 83% raised

More information

Association of [ 2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer

Association of [ 2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer Association of [ 2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer Jeffrey J. Tosoian,*, Stacy Loeb,*, Zhaoyong Feng, Sumit Isharwal, Patricia Landis, Debra J. Elliot,

More information

Oncology: Prostate/Testis/Penis/Urethra

Oncology: Prostate/Testis/Penis/Urethra Oncology: Prostate/Testis/Penis/Urethra Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates Bimal

More information

Hyoung Woo Kim, Dae Geun Moon, Hyun Min Kim, Jong Ho Hwang, Soon Chan Kim, Sam Geuk Nam, Jun Tag Park

Hyoung Woo Kim, Dae Geun Moon, Hyun Min Kim, Jong Ho Hwang, Soon Chan Kim, Sam Geuk Nam, Jun Tag Park www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.10.681 Voiding Dysfunction Effect of Shifting from Combination Therapy to Monotherapy of α-blockers or 5α-Reductase Inhibitors on Prostate Volume

More information

BPH AND BEYOND. BPSA: A Novel Serum Marker for Benign Prostatic Hyperplasia Kevin M. Slawin, MD, Shahrokh Shariat, MD, Eduardo Canto, MD

BPH AND BEYOND. BPSA: A Novel Serum Marker for Benign Prostatic Hyperplasia Kevin M. Slawin, MD, Shahrokh Shariat, MD, Eduardo Canto, MD BPH AND BEYOND B: A Novel Serum Marker for Benign Prostatic Hyperplasia Kevin M. Slawin, MD, Shahrokh Shariat, MD, Eduardo Canto, MD Baylor Prostate Center, The Scott Department of Urology, Baylor College

More information

Introduction. Growths in the prostate can be benign (not cancer) or malignant (cancer).

Introduction. Growths in the prostate can be benign (not cancer) or malignant (cancer). This information was taken from urologyhealth.org. Feel free to explore their website to learn more. Another trusted website with good information is the national comprehensive cancer network (nccn.org).

More information

All about the Prostate

All about the Prostate MEN S HEALTH Dr Nick Pendleton January 16 th 2018 All about the Prostate 1 What does it do? Functions of the Prostate 1. Secretes Prostatic Fluid slightly alkaline fluid, 30% of volume of seminal fluid,

More information

USA Preventive Services Task Force PSA Screening Recommendations- May 2018

USA Preventive Services Task Force PSA Screening Recommendations- May 2018 GPGU - NOTÍCIAS USA Preventive Services Task Force PSA Screening Recommendations- May 2018 Rationale Importance Prostate cancer is one of the most common types of cancer that affects men. In the United

More information

Prostate Cancer Screening: Risks and Benefits across the Ages

Prostate Cancer Screening: Risks and Benefits across the Ages Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our

More information

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer

Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon

More information

Reducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study

Reducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study Reducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study Luke Witherspoon MD MSc, Johnathan L. Lau BSc, Rodney H. Breau MD MSc, Christopher

More information

α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years Long-Term Results

α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years Long-Term Results www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.4.248 Voiding Dysfunction α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia;

More information

Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement

Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement Clinical Review & Education JAMA US Preventive Services Task Force RECOMMENDATION STATEMENT Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement US Preventive Services

More information

Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma

Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma Disease Markers 19 (2003,2004) 287 292 287 IOS Press Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma V. Thakur a,, P.P. Singh b, M. Talwar c and U. Mukherjee

More information

Determination of An Optimum Cut-off Point for % fpsa/tpsa to Improve Detection of Prostate Cancer

Determination of An Optimum Cut-off Point for % fpsa/tpsa to Improve Detection of Prostate Cancer Original Article DOI: 10.21276/APALM.1254 Determination of An Optimum Cut-off Point for % fpsa/tpsa to Improve Detection of Prostate Cancer Vineeth* G Nair and M. H. Shariff Department of Pathology, Yenepoya

More information

Mercy s Cancer Program 2014 Update

Mercy s Cancer Program 2014 Update Mercy s Cancer Program 2014 Update Mercy Hospital & Medical Center is accredited Academic Comprehensive Cancer Program by the American College of Surgeon s Commission on Cancer. This study is directed

More information

PSA SCREENING FOR PROSTATE CANCER

PSA SCREENING FOR PROSTATE CANCER Policy Paper on PSA SCREENING FOR PROSTATE CANCER Has the time come to reconsider structured population-based PSA screening for prostate cancer? 1 2 Table of contents Table of Contents 1 EXECUTIVE SUMMARY

More information

Prostate Cancer Screening: Navigating the Controversy

Prostate Cancer Screening: Navigating the Controversy Prostate Cancer Screening: Navigating the Controversy 2 William M. Hilton, Ian M. Thompson Jr., and Dipen J. Parekh Despite advances in diagnosis, treatment, and patient outcomes, prostate cancer remains

More information

Financial Disclosures. Prostate Cancer Screening and Surgical Management

Financial Disclosures. Prostate Cancer Screening and Surgical Management Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Financial Disclosures

More information

Screening for Prostate Cancer

Screening for Prostate Cancer clinical practice Screening for Prostate Cancer Richard M. Hoffman, M.D., M.P.H. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies

More information

Overdiagnosis. Making people sick in the pursuit of health Drs Gilbert Welch, Lisa Schwartz, Steven Woloshin

Overdiagnosis. Making people sick in the pursuit of health Drs Gilbert Welch, Lisa Schwartz, Steven Woloshin Overdiagnosis Making people sick in the pursuit of health Drs Gilbert Welch, Lisa Schwartz, Steven Woloshin Screening for prostate cancer «Screening for prostate cancer has become the poster child of overdiagnosis

More information

BPH with persistently elevated PSA 아주대학교김선일

BPH with persistently elevated PSA 아주대학교김선일 BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547

More information

Diagnosis and management of prostate cancer in the

Diagnosis and management of prostate cancer in the Diagnosis and management of prostate cancer in the Jeremy Teoh ( 張源津 ) Assistant Professor, Department of Surgery, The Chinese University of Hong Kong. Email: jeremyteoh@surgery.cuhk.edu.hk Estimated age-standardised

More information

Objectives. Prostate Cancer Screening and Surgical Management

Objectives. Prostate Cancer Screening and Surgical Management Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Objectives Update

More information

Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance

Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance ORIGINAL ARTICLE (2011) 14, 53 57 & 2011 Macmillan Publishers Limited All rights reserved 1365-7852/11 www.nature.com/pcan Relationship between initial PSA density with future PSA kinetics and repeat biopsies

More information

Prostate Cancer Screening & Treatment Updates. Daniel Gilbert, D.O. 4/2017

Prostate Cancer Screening & Treatment Updates. Daniel Gilbert, D.O. 4/2017 Prostate Cancer Screening & Treatment Updates Daniel Gilbert, D.O. 4/2017 1 www.drgilberturology.com Prostate Cancer Screening 2 Disclosures, Sponsors & Locations Nothing to disclose, No sponsors Hospital

More information

Canadian Urological Association recommendations on prostate cancer screening and early diagnosis

Canadian Urological Association recommendations on prostate cancer screening and early diagnosis CUA GUIDELINE Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Ricardo A. Rendon, MD 1 ; Ross J. Mason, MD 2 ; Karim Marzouk, MD 3 ; Antonio Finelli, MD

More information

Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection

Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection DOI 10.1186/s40064-016-3176-3 RESEARCH Open Access Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection Yuxiao Zheng, Yuan Huang, Gong

More information

J Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer

More information

Prostate gland disorder พ.ต.ต.นพ.ส ร ต ก ตต ศ ภพร นพ.(สบ.2) โรงพยาบาลต ารวจ ส าน กงานต ารวจแห งชาต

Prostate gland disorder พ.ต.ต.นพ.ส ร ต ก ตต ศ ภพร นพ.(สบ.2) โรงพยาบาลต ารวจ ส าน กงานต ารวจแห งชาต Prostate gland disorder พ.ต.ต.นพ.ส ร ต ก ตต ศ ภพร นพ.(สบ.2) โรงพยาบาลต ารวจ ส าน กงานต ารวจแห งชาต Prostate cancer Overview Diagnosis Treatment Lower urinary tract symptoms EPIDEMIOLOGY The most common

More information

Oncology: Prostate/Testis/Penis/Urethra. Prostate Specific Antigen Testing Among the Elderly When To Stop?

Oncology: Prostate/Testis/Penis/Urethra. Prostate Specific Antigen Testing Among the Elderly When To Stop? Oncology: Prostate/Testis/Penis/Urethra Prostate Specific Antigen Testing Among the Elderly When To Stop? Edward M. Schaeffer,*, H. Ballentine Carter, Anna Kettermann, Stacy Loeb, Luigi Ferrucci, Patricia

More information

Cost-effectiveness of a new urinary biomarkerbased risk score compared to standard of care in prostate cancer diagnostics a decision analytical model

Cost-effectiveness of a new urinary biomarkerbased risk score compared to standard of care in prostate cancer diagnostics a decision analytical model Cost-effectiveness of a new urinary biomarkerbased risk score compared to standard of care in prostate cancer diagnostics a decision analytical model Siebren Dijkstra*, Tim M. Govers, Rianne J. Hendriks*,

More information

White Paper: To Screen or Not to Screen?

White Paper: To Screen or Not to Screen? White Paper: To Screen or Not to Screen? Prof Chris Bangma, one of the ERSPC directors, sets this challenge for health authorities in the light of their recent study into the benefits of population based

More information

Prostate cancer screening: a wobble Balance. Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph

Prostate cancer screening: a wobble Balance. Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph Prostate cancer screening: a wobble Balance Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph Epidemiology Most common non skin malignancy in men in developed countries Third leading

More information

Prostate-Specific Antigen Testing in Tyrol, Austria: Prostate Cancer Mortality Reduction Was Supported by an Update with Mortality Data up to 2008

Prostate-Specific Antigen Testing in Tyrol, Austria: Prostate Cancer Mortality Reduction Was Supported by an Update with Mortality Data up to 2008 Prostate-Specific Antigen Testing in, Austria: Prostate Cancer Mortality Reduction Was Supported by an Update with Mortality Data up to 2008 The Harvard community has made this article openly available.

More information

Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors

Since the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors 2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.

More information

In 2008, the United States Preventive Services

In 2008, the United States Preventive Services CMAJ Analysis CME Prostate-specific antigen screening can be beneficial to younger and at-risk men Monique J. Roobol PhD Msc, Chris H. Bangma MD PhD, Stacy Loeb MD In 2008, the United States Preventive

More information

UC San Francisco UC San Francisco Previously Published Works

UC San Francisco UC San Francisco Previously Published Works UC San Francisco UC San Francisco Previously Published Works Title Expected population impacts of discontinued prostate-specific antigen screening Permalink https://escholarship.org/uc/item/5fd7z6j0 Journal

More information

Implications of Prostate Specific Antigen and its Molecular Derivatives in the Management of Carcinoma Prostate

Implications of Prostate Specific Antigen and its Molecular Derivatives in the Management of Carcinoma Prostate Review Article DOI: 10.17354/ijss/2015/327 Implications of Prostate Specific Antigen and its Molecular Derivatives in the Management of Carcinoma Prostate Sujan Narayan Agrawal 1, Chanjiv Singh 2, Sanwal

More information

Response to United States Preventative Services Task Force draft PSA Screening recommendation: Donald B. Fuller, M.D. Genesis Healthcare Partners

Response to United States Preventative Services Task Force draft PSA Screening recommendation: Donald B. Fuller, M.D. Genesis Healthcare Partners Response to United States Preventative Services Task Force draft PSA Screening recommendation: Donald B. Fuller, M.D. Genesis Healthcare Partners October 2011 Cancer Incidence Statistics, 2011 CA: A Cancer

More information

SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE. A. AMAYO and W.

SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE. A. AMAYO and W. 22 EAST AFRICAN MEDICAL JOURNAL January 2004 The East African Medical Journal Vol. 81 No. 1 January 2004 SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE.

More information

Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice

Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice A microsimulation screening analysis Carlsson, Sigrid V.; de Carvalho, Tiago M.;

More information

The Impact of MRI-TRUS Cognitively Targeted Biopsy on the Incidence of Pathologic Upgrading After Radical Prostatectomy

The Impact of MRI-TRUS Cognitively Targeted Biopsy on the Incidence of Pathologic Upgrading After Radical Prostatectomy Original Article World J Nephrol Urol. 2018;7(1):12-16 The Impact of MRI-TRUS Cognitively Targeted Biopsy on the Incidence of Pathologic Upgrading After Radical Prostatectomy Ragheed Saoud a, Albert El-Haj

More information

The population of subjects which was statistically analyzed was the Intent-to-Treat population

The population of subjects which was statistically analyzed was the Intent-to-Treat population Study No.: ARIB3003 (Year 1) Title: A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel-Group Study of the Efficacy and Safety of GI198745 in the Treatment and Modification of Progression

More information